People: Novartis AG (NVS)

NVS on New York Consolidated

94.57USD
18 Dec 2014
Price Change (% chg)

-- (--)
Prev Close
$94.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,367,522
52-wk High
$96.97
52-wk Low
$76.60

Search Stocks

Summary

Name Age Since Current Position

Joerg Reinhardt

58 2013 Chairman of the Board

Joseph Jimenez

54 2010 Chief Executive Officer, Member of the Executive Committee

Ulrich Lehner

68 2006 Vice Chairman of the Board of Directors, Non-Executive Director

Harry Kirsch

2013 Member of the Management Board, Chief Financial Officer

Peter Kornicker

2011 Chief Compliance Officer

Felix Ehrat

57 2012 Group General Counsel, Member of the Executive Committee

Juergen Brokatzky-Geiger

62 2005 Head Human Resources and Member of the Executive Committee

Michele Galen

2012 Head Communications

Paul van Arkel

2013 Head of Corporate Strategy and External Affairs

Erwin Vanhaecke

2013 Head Novartis Group Quality

Brian McNamara

2013 Member of the Management Board, Division Head, Novartis OTC

Kevin Buehler

2011 Member of the Executive Committee, Division Head, Alcon

David Epstein

52 2010 Member of the Executive Committee, Division Head, Pharmaceuticals

Mark Fishman

62 2002 Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)

Jeffrey George

40 2010 Member of the Executive Committee and Division Head, Sandoz

George Gunn

63 2011 Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility

Andrin Oswald

42 2008 Member of the Executive Committee, Division Head, Vaccines and Diagnostics

Charlotte Pamer-Wieser

2011 Corporate Secretary

Dimitri Azar

55 2012 Member of the Board of Directors

William Brody

70 2009 Member of the Board of Directors

Srikant Datar

61 2003 Member of the Board of Directors

Ann Fudge

63 2008 Member of the Board of Directors

Pierre Landolt

67 1996 Member of the Board of Directors

Enrico Vanni

63 2011 Member of the Board of Directors

Andreas von Planta

58 2006 Member of the Board of Directors

Wendelin Wiedeking

62 2003 Member of the Board of Directors

Rolf Zinkernagel

70 1999 Member of the Board of Directors

Verena Briner

2013 Non-Executive Independent Member of the Board

Charles Sawyers

2013 Non-Executive Independent Member of the Board

William Winters

2013 Non-Executive Independent Member of the Board

Samir Shah

2013 Global Head Investor Relations

Biographies

Name Description

Joerg Reinhardt

Mr. Joerg Reinhardt, Ph.D. has been Chairman of the Board of Directors of Novartis AG since August 2013. He is Chairman of the Chairman's Committee. Dr. Reinhardt previously served as chairman of the board of management and the executive committee of Bayer HealthCare. Prior to that, he served as Chief Operating Officer of Novartis from 2008 to 2010, and as Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. He also served as Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010; as a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004; and as a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013. He is currently a member of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Dr. Reinhardt graduated with a Ph.D. in pharmaceutical sciences from Saarland University in Germany. He joined Sandoz Pharma Ltd. in 1982 and held various positions including Head of Development. Following the merger that created Novartis in 1996, Dr. Reinhardt became Head of Preclinical Development and Project Management at Novartis, and assumed the position of Head of Pharmaceutical Development in 1999. His leadership, Global and Industry experience include being former chairman of global healthcare company; former COO of Novartis and former Chairman of Novartis research institution; former board member of biotechnology company; former board member of global supplier for pharmaceutical, healthcare, and life sciences industries; member of global non-profit representing pharmaceutical industry.

Joseph Jimenez

Mr. Joseph S. Jimenez has been Chief Executive Officer and Member of the Executive Committee of Novartis AG since February 1, 2010. Prior to that, he served as CEO - Pharmaceuticals Division as of October 2007. In the Company he is responsible for heading the Company's diversified healthcare portfolio of innovative pharmaceuticals, generics, vaccines and diagnostics and consumer health products. Previously, Mr. Jimenez served as Division Head, Novartis Pharmaceuticals. Mr. Jimenez joined Novartis in April 2007 as Division Head, Novartis Consumer Health. Previously, he served as President and Chief Executive Officer (CEO) of the North America business for the H.J. Heinz Company and as President and CEO of Heinz in Europe from 2002 to 2006. Prior to joining Novartis, he was a Non-Executive Director of Astra-Zeneca plc, United Kingdom, from 2002 to 2007. He was also an advisor for the private equity organization Blackstone Group in the United States. Mr. Jimenez is Member of the Board of Directors of Colgate-Palmolive. He graduated with a bachelors degree from Stanford University in 1982 and with a Master of Business Administration (MBA) degree from the University of California, Berkeley, in 1984.

Ulrich Lehner

Prof. Dr. Ulrich Lehner, Ph.D., has been Vice Chairman of the Board of Directors and Non-Executive Director of Novartis AG since 2006. He serves as Chairman of the Corporate Governance and Nomination Committee of the Company, as well as Member of the Audit and Compliance Committee, the Risk Committee, the Chairman’s Committee, and the Compensation Committee. He has acted as Non-Executive Director and Member of the Board of Directors of the Company since 2002. He has also co-woorked with the Audit Committee. From 1975 to 1981, he was an auditor with KPMG Deutsche Treuhand-Gesellschaft AG in Duesseldorf. In 1981, he joined Henkel KGaA. After heading the Controlling Department of Fried. Krupp GmbH in Germany from 1983 to 1986, Prof. Lehner returned to Henkel as Finance Director. From 1991 to 1994, he headed Henkel Asia-Pacific Ltd in Hong Kong, and from 1995 to 2000, served as Executive Vice President, Finance/Logistics, of Henkel KGaA. From 2000 to 2008, Prof. Lehner served as Chairman of the Management Board of Henkel KGaA. Prof. Lehner is Member of the Shareholders’ Committee of Henkel AG & Co. KGaA, Chairman of the Supervisory Board of Deutsche Telekom AG, and serves as Member of the Supervisory Boards of E.ON AG, ThyssenKrupp AG, Porsche Automobil Holding SE and Henkel Management AG, all in Germany. He is also Member of the Shareholders’ Committees of Dr. August Oetker KG and Krombacher Brauerei, both in Germany. Prof. Lehner graduated in business administration and mechanical engineering from Technische Universitaet Darmstadt (the Darmstadt University of Technology), Germany, in 1975.

Harry Kirsch

Mr. Harry Kirsch has been appointed as Member of the Management Board, Chief Financial Officer of Novartis AG since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and previously served as CFO of the Company’s Pharmaceuticals Division. At Novartis, he also served as CFO of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G's global pharmaceuticals business. Prior to that, he held finance positions in different categories of P&G's consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch studied industrial engineering and economics at the University of Karlsruhe in Germany (Diplom Wirtschaftsingenieur).

Peter Kornicker

Dr. Peter Kornicker has been Chief Compliance Officer at Novartis AG since January 2011. He leads the Integrity & Compliance Function, which designs and implements compliance programs associated with the Novartis Code of Conduct, Anti-Bribery Policy and Professional Practices Policies. Mr. Kornicker joined Novartis in 1994 and has held legal roles of increasing responsibility in Switzerland and the United States at business units including Pharmaceuticals, Animal Health, Corporate, and Consumer Health. Prior to being appointed Chief Compliance Officer, he served as Global General Counsel for the Consumer Health Division. Mr. Kornicker received his law degree in 1991 and his doctorate in 1993 from the University of Basel. He was admitted to the bar in 1994.

Felix Ehrat

Dr. Felix R. Ehrat, Ph.D., has been Group General Counsel and Member of the Executive Committee of Novartis AG since January 1, 2012. He joined the Company in October 2011 as General Counsel and a permanent attendee of the Executive Committee. Dr. Ehrat is a practitioner of corporate, banking, and mergers and acquisitions law, as well a in corporate governance and arbitration. He started his career as an associate with Baer & Karrer Ltd. in Zurich in 1987, became Partner in 1992, and advanced to Senior Partner (2003 to 2011) and Executive Chairman of the Board (2007 to 2011) of the firm. Dr. Ehrat is Chairman of Globalance Bank AG in Switzerland, and Member of the Board of Liechtensteinische Landesbank AG in Liechtenstein. Previously, Dr. Ehrat was Chairman of Banca del Gottardo, and a Board Member of Julius Baer Holding AG, Austriamicrosystems AG, Charles Voegele Holding AG, and Carlo Gavazzi Holding AG. Mr. Ehrat was admitted to the Zurich bar in 1985 and received his doctorate of law from Universitaet Zuerich (the University of Zurich) in 1990. In 1986, he completed an LL.M. at McGeorge School of Law in the United States. His past memberships and positions include: the International Bar Association, where he was co-chair of the Committee on Corporate and M&A Law from 2007 to 2008; Association Internationale des Jeunes Avocats, where he was president from 1998 to 1999; and the Swiss Arbitration Association, the Zurich Bar Association, and the Swiss Bar Association.

Juergen Brokatzky-Geiger

Dr. Juergen Brokatzky-Geiger, Ph.D., has been Head Human Resources and Member of the Executive Committee at Novartis AG since January 1, 2005. Prior to that he served as Director of Human Resources at the Company from September 1, 2003. He joined Ciba-Geigy Ltd in 1983 as a Laboratory Head in the Pharmaceuticals Division. After a job rotation in the United States, he held positions of increasing responsibility in Research and Development (R&D) including Group Leader of Process R&D, Head of Process R&D, and Head of Process Development and Pilot Plant Operations. During the merger of Ciba-Geigy and Sandoz in 1996, Mr. Brokatzky-Geiger was appointed Integration Officer of Technical Operations. He later became the Head of Chemical and Analytical Development and served as the Global Head of Technical R&D from 1999 to August 2003. He graduated with a Doctorate in Philosophy (Ph.D.) in chemistry from Albert-Ludwigs-Universitaet Freiburg (the University of Freiburg), Germany, in 1982.

Michele Galen

Ms. Michele Galen serves as Head Communications of Novartis AG since January 2012. Prior to this appointment, Ms. Galen served as Vice President and Global Head, Communications and Advocacy for Novartis Pharmaceuticals, based in Basel, Switzerland. Ms. Galen joined Novartis Pharmaceuticals Corporation (NPC) in the US in 2001. During her tenure at Novartis, she also served as Vice President and Global Head, Oncology Affairs; Vice President and Global Head, Communications and External Affairs for Novartis Molecular Diagnostics; and Vice President, Corporate Communications, NPC. Prior to joining Novartis Pharmaceuticals, Ms. Galen was a Managing Director in the Corporate Practice at a global public relations firm in New York specializing in change communication, issues management and strategic philanthropy. She also is an award-winning journalist, was Editor at Business Week magazine and served as a board member of the Global Health Council. She is a member of the New York State Bar and practiced at Stroock, Stroock + Lavan, and Skadden, Arps, Slate, Meagher & Flom. Ms. Galen received a B.A. from George Washington University, a master’s degree from the Columbia University Graduate School of Journalism, and a J.D. from New York University School of Law.

Paul van Arkel

Mr. Paul van Arkel has been Head of Corporate Strategy and External Affairs at Novartis AG since May 2013. Prior to joining Novartis, Mr. van Arkel was a partner at McKinsey & Company, specializing in pharmaceuticals and medical products. At McKinsey, he led the company’s pharmaceutical marketing work in Europe, the Middle East, and Africa, as well as its work on pharmaceutical launches worldwide. Mr. van Arkel previously served as a consultant and later a partner at Monitor Group, initially focusing on corporate strategy across industries, and eventually moving to marketing and sales in pharmaceuticals and medical devices. Mr. van Arkel received a diploma in public administration from Leiden University in the Netherlands, and a master’s degree in business administration from Erasmus University, also in the Netherlands.

Erwin Vanhaecke

Mr. Erwin Vanhaecke, Ph.D., serves as Head Novartis Group Quality at Novartis AG since January 2013. Mr. Vanhaecke previously served as Senior Vice President, Global Quality Operations at Alcon. He joined Alcon in 1990 as Quality Assurance Manager of the manufacturing facility in Belgium. Since then, his other roles have included Quality Assurance/Regulatory Affairs Manager, Northern Europe; Group Director, Quality Assurance; Vice President, Corporate Quality Assurance – Pharmaceutical; Vice President, Corporate Quality Assurance – Surgical Products; and Vice President, Global Quality Assurance and Compliance. Prior to joining Alcon, Mr. Vanhaecke served as a researcher and lecturer in pharmaceutical microbiology at the State University of Ghent in Belgium, where he earned a degree in pharmacy and a Ph.D. in pharmaceutical sciences. He also received a post-graduate degree in management from the VLEKHO School in Brussels, Belgium.

Brian McNamara

Mr. Brian McNamara serves as Member of the Management Board, Division Head, Novartis OTC at Novartis AG as of January 1, 2013. Prior to this role, Mr. McNamara served as President, Americas Region, for Novartis OTC. Since joining Novartis OTC in 2004 as Senior Vice President and General Manager of Novartis OTC North America, Mr. McNamara has worked on a number of strategic initiatives. Mr. McNamara also served as President of Novartis OTC Europe from 2007 until 2010. Mr. McNamara began his career at Procter & Gamble Co., Cincinnati, United States, where he gained experience in consumer and brand marketing, product supply, and customer leadership. Mr. McNamara has served on the board of directors and the executive committee of the Consumer Healthcare Products Association in the United States. He is also a former board member of the Association of the European Self-Medication Industry and chairman of its economic affairs committee.

Kevin Buehler

Mr. Kevin J. Buehler has been Member of the Executive Committee and Division Head, Alcon at Novartis AG since April 2011. Mr. Buehler was President and Chief Executive Officer of Alcon Inc. from 2009 to 2011. He began his career with Alcon in 1984 as a Regional Sales Manager in the Consumer Products Division, and held positions of increasing responsibility before being named Director of Sales and Marketing. In 1996, he became Director of Alcon’s United States (US) Managed Care and Falcon Generic Pharmaceutical groups, and became Vice President in 1998. The following year he returned to the US Consumer Products Division as Vice President and General Manager. Mr. Buehler moved to the International Division in 2002 as Vice President and Regional Manager, Latin America and Caribbean. He was later named Area Vice President, Latin America, Canada, Australia and Far East. Mr. Buehler also served as Senior Vice President, global markets, and Chief Marketing Officer. Prior to joining Alcon, he worked for The Gillette Co. and Snyder Drug Stores. Mr. Buehler holds a Bachelor of Science degree from Carroll University in Waukesha, Wis., in the United States, with concentrations in business administration and political science. He completed the Harvard Program for Management Development in 1993.

David Epstein

Mr. David R. Epstein has been Member of the Executive Committee and Division Head, Pharmaceuticals at Novartis AG since February 1, 2010. Prior to his current position, Mr. Epstein served as Head of Novartis Oncology since 2000. He led the Molecular Diagnostics unit of the Company since 2008. He is a permanent attendee of the Executive Committee of Novartis. Before joining Novartis, Mr. Epstein was an associate in the Strategy Practice of the consulting firm, Booz Allen & Hamilton. Mr. Epstein joined Sandoz, a predecessor company of Novartis, in 1989, and held various leadership positions of increasing responsibility for the company, including Chief Operating Officer of Novartis Pharmaceuticals Corporation in the United States and Head of Novartis Specialty Medicines. Mr. Epstein graduated with a bachelors degree in pharmacy from Rutgers University College of Pharmacy in 1984, and with a Master of Business Administration in finance and marketing from New York’s Columbia University Graduate School of Business in 1987.

Mark Fishman

Dr. Mark C. Fishman, M.D., has served as Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) at Novartis AG since 2002. Before joining Novartis in 2002, Dr. Fishman was Chief of Cardiology and Director of the Cardiovascular Research Center at Massachusetts General Hospital, and Professor of Medicine at Harvard Medical School, both in the United States. Dr. Fishman has worked with national policy and scientific committees, including those of the United States National Institutes of Health (NIH) and the Wellcome Trust. He completed his internal medicine residency, chief residency and cardiology training at Massachusetts General Hospital. Dr. Fishman graduated with a bachelors degree from Yale College in 1972 and a Doctorate of Medicine (M.D.) from Harvard Medical School in 1976. He has been honored with awards and distinguished lectureships, and is Member of the Institute of Medicine of the National Academies (the United States) and a Fellow of the American Academy of Arts and Sciences.

Jeffrey George

Mr. Jeffrey (Jeff) George has been Member of the Executive Committee and Division Head, Sandoz at Novartis AG since 2010. He has been Division Head, Sandoz since 2008. Before joining Novartis, Mr. George was a Senior Director of Strategy and Business Development at Gap Inc. From 2001 to 2004, he was with McKinsey & Company in San Francisco, United States, where he was an Engagement Manager. Mr. George joined Novartis in the Vaccines and Diagnostics Division in January 2007 as Head of Commercial Operations for Western and Eastern Europe, then advanced to Head of Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharma. Mr. George graduated in 1999 with a Master’s degree from the Johns Hopkins University School of Advanced International Studies, where he studied international economics and emerging markets political economy. He received a Master of Business Administration from Harvard University in 2001.

George Gunn

Mr. George Gunn has served as Member of the Executive Committee, Division Head, Novartis Animal Health; and Head of Corporate Responsibility at Novartis AG since March 2011. Prior to that, he acted as Division Head Consumer Health and Member of the Executive Committee at the Copmany since December 2008. Before joining Novartis AG, Mr. Gunn was President of Pharmacia Animal Health, based in the United States. Previously, he spent more than 15 years in positions of increasing responsibility in healthcare companies. He worked as a veterinary surgeon for nine years before joining the industry. Mr. Gunn joined Novartis in 2003 as Head of Novartis Animal Health, North America. In January 2004, he assumed his position as Head of the Animal Health Business Unit. In addition to this role, he was appointed Head of the Consumer Health Division in December 2008. Mr. Gunn graduated with a bachelor of veterinary medicine and surgery degree from the Royal (Dick) School of Veterinary Studies in the United Kingdom, in 1973. He graduated with a diploma in veterinary state medicine from the same school in 1978. In 2008, he received an honorary doctorate in veterinary medicine and surgery from the University of Edinburgh. He is Member of the Royal College of Veterinary Surgeons (MRCVS).

Andrin Oswald

Dr. Andrin Oswald, M.D., has been Member of the Executive Committee and Division Head of Vaccines and Diagnostics at Novartis AG since 2008. He is Permanent Attendee of the Executive Committee of Novartis AG. Before joining Novartis, Dr. Oswald was Delegate of the International Committee of the Red Cross to Nepal from 2002 to 2003 and worked with McKinsey & Company, Switzerland. In 2005, Dr. Oswald joined Novartis and advanced from Assistant to the Chairman and Chief Executive Officer (CEO), to Head of the Country Pharma Organization (CPO) and Country President for Novartis in South Korea, to CEO of Speedel and Global Head of Development Franchises at Novartis Pharma in 2008. Dr. Oswald graduated with a Doctorate in Medicine (M.D.) from the University of Geneva, Switzerland, in 1999.

Charlotte Pamer-Wieser

Ms. Charlotte Pamer-Wieser, Ph.D. serves as Corporate Secretary at Novartis AG since September 2011. In 2004, Ms. Pamer-Wieser started her professional career as associate at Walder Wyss Ltd., in Zurich, Switzerland. From 2007 to 2011, she worked as senior associate for Bär & Karrer Ltd. in Zurich. Her areas of specialization include corporate law, mergers and acquisitions, company reorganizations and banking and finance law. Ms. Pamer-Wieser received a Ph.D. from the University of Basel, Switzerland, and holds a master’s degree in law (LL.M.) from the University of Chicago Law School. In 2002, she was admitted to the Basel bar, and from 2007 to 2010 she was a lecturer at the University of Basel. Ms. Pamer-Wieser has written several articles on corporate law and is a member of the “Association des Jeunes Avocats” (aija) and the American Law and Economics Association.

Dimitri Azar

Dr. Dimitri Azar, M.D., has served as Member of the Board of Directors of Novartis AG since February 2012. He qualifies as an independent Non-Executive Director. He is Dean of the College of Medicine and professor of ophthalmology, bioengineering and pharmacology at the University of Illinois at Chicago in the United States, where he formerly was Head of the Department of Ophthalmology and Visual Sciences. He sits on the Board of Trustees of the Chicago Ophthalmological Society and the Association of Research in Vision and Ophthalmology. Dr. Azar is Member of the American Ophthalmological Society and holds committee positions with the American Academy of Ophthalmology. Dr. Azar began his career at the American University Medical Center, Beirut, Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School in the United States. Dr. Azar practiced at the Wilmer Ophthalmologic Institute at The Johns Hopkins Hospital School of Medicine, then returned to the Massachusetts Eye and Ear Infirmary as director of the cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds an Executive Master of Business Administration from the University of Chicago, Booth School of Business.

William Brody

Dr. William R. Brody, M.D., Ph.D., serves as Member of the Board of Directors at Novartis AG since February 2009. He is also Member of the Compensation Committee of the Company. Dr. Brody was President of the Johns Hopkins University until the end of 2008 and is President of the United States-based Salk Institute for Biological Studies, La Jolla, California, United States. Previously he held various academic positions, including Professor for Radiology and Electrical Engineering at Stanford University and Professor and Director of the Department of Radiology at the Johns Hopkins University, both in the United States. Dr. Brody is President of the Salk Institute for Biological Studies. He is also Member of the Boards of Directors of the United States-based International Business Machines Corp. and Kool Smiles Inc., and the mutual funds boards of T. Rowe Price. He is Member of numerous professional associations, and also serves on the advisory boards of various government and nonprofit organizations. Dr. Brody earned his bachelors and masters degrees in electrical engineering from the Massachusetts Institute of Technology before completing his M.D. and Ph.D. at Stanford University, all in the United States.

Srikant Datar

Dr. Srikant Datar, Ph.D., has been Member of the Board of Directors of Novartis AG since 2003. He qualifies as Independent Non-Executive Director. He is Chairman of the Audit and Compliance Committee and Member of the Risk Committee and the Compensation Committee at the Company. Dr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University in the United States. His research interests are in the areas of cost management, measurement of productivity, product development, timebased competition, incentives and performance evaluation. He is the author of a number of scientific publications and has received several academic awards and honors. Dr. Datar has advised and worked with numerous companies in research, development and training. Dr. Datar is Arthur Lowes Dickinson Professor at the Graduate School of Business Administration at Harvard University. He is also Member of the Board of Directors of ICF International Inc. and of Stryker Corp., both in the United States, and of KPIT Cummins Infosystems Ltd., India. He graduated with distinction in mathematics and economics from the University of Bombay, India, in 1973. He is a Chartered Accountant and holds two masters degrees and a Doctor of Philosophy (Ph.D.) from Stanford University, United States.

Ann Fudge

Ms. Ann M. Fudge has been Member of the Board of Directors at Novartis AG since February 26, 2008. She qualifies as an Independent Non-Executive Director. She is Member of the Risk Committee as well as Corporate Governance and Nomination Committee of the Company. She is former Chairwoman and Chief Executive Officer of Young & Rubicam Brands. Before that, she served as President of the Beverages, Desserts and Post Division of Kraft Foods. Ms. Fudge serves on the Board of Directors of General Electric Co., on the Board of Directors of Unilever, United Kingdom /Netherlands and on the Board of Directors of Infosys, India. She is a trustee of the New York-based Rockefeller Foundation and the Atlanta-based Morehouse College, and Chairman of the United States Programs Advisory Panel of the Bill & Melinda Gates Foundation. Ms. Fudge is further Member of the Harvard University Corporation Committee on Finance. She also sits on the Board of the Council on Foreign Relations. Ms. Fudge received her Bachelors degree from Simmons College and her Masters of Business Administration degree from Harvard University Graduate School of Business in the United States.

Pierre Landolt

Dr. Pierre Landolt, Ph.D., serves as Member of the Board of Directors at Novartis AG since 1996. He is Member of the Corporate Governance and Nomination Committee at the Company. From 1974 to 1976, he worked for Sandoz Brazil SA. In 1977, he acquired an agricultural estate in the semi-arid Northeast Region of Brazil and, over several years, converted it into a model farm in organic and biodynamic production. Since 1997, Dr. Landolt has been Associate and Chairman of AxialPar Ltda, Brazil, an investment company focused on sustainable development, with investments in fish farming, soybean for human consumption and organic vegetable. In 2000, he co-founded EcoCarbone SA, France, a company active in the design and development of carbon-sequestration processes in Asia, Africa, South America and Europe. In 2007, he co-founded Amazentis SA, Switzerland, a startup company active in the convergence space of medication and nutrition. He is a Member of the Board of Directors of Syngenta AG and a Partner with unlimited liabilities of the Swiss private bank Landolt & Cie. In Brazil, Dr. Landolt serves as President of the Instituto Fazenda Tamandua, the Instituto Estrela de Fomento ao Microcredito, AxialPar Ltda. and Moco Agropecuaria Ltda. In Switzerland, he is Chairman of Emasan AG and Vaucher Manufacture Fleurier SA, Vice Chairman of Parmigiani Fleurier SA, and is on the Board of the Syngenta Foundation for Sustainable Agriculture. He is Member of the Board of EcoCarbone SA, France, and Swiss Amazentis SA. He is also Vice Chairman of the Montreux Jazz Festival Foundation. Dr. Landolt graduated with a Bachelors degree in Law from the University of Paris-Assas.

Enrico Vanni

Dr. Enrico Vanni, Ph.D., has been Member of the Board of Directors at Novartis AG since 2011. He qualifies as an Independent Non-Executive Director. He is Member of the Audit and Compliance Committee, and Chairman of the Compensation Committee at the Company. He began his career as a research engineer at International Business Machines Corp. in California, and joined McKinsey & Company in Zurich, Switzerland, in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led its European pharmaceutical practice and served as Member of the Partner review committee of the firm prior to his retirement in 2007. Since his retirement as Director of McKinsey & Company in 2007, Dr. Vanni has been an independent consultant. He is currently Member of several Boards of Directors in industries from healthcare to private banking, for nonlisted companies including Eclosion2, Denzler & Partners SA and Banque Privee BCP (Suisse) SA. Dr. Vanni holds an engineering degree in chemistry from Ecole polytechnique federale de Lausanne (the Federal Polytechnic School of Lausanne), Switzerland, a Ph.D. in chemistry from Universite de Lausanne, as well as a Master of Business Administration from INSEAD in Fontainebleau, France.

Andreas von Planta

Dr. Andreas von Planta, Ph.D., has been Member of the Board of Directors at Novartis AG since February 28, 2006. He qualifies as an independent Non-Executive Director of the Company. He is Chairman of the Risk Committee, Member of the Audit and Compliance Committee, and the Corporate Governance and Nomination Committee at the Company. He passed his bar examinations in Basel in 1982. Since 1983, he has been working for the law firm Lenz & Staehelin in Geneva, where he became a partner in 1988. His areas of specialization include corporate law, corporate finance, company reorganizations, and mergers and acquisitions. Mr. von Planta is Chairman of the Schweizerische National-Versicherungs-Gesellschaft AG and a Board Member of Holcim Ltd., both in Switzerland. He is also a Board Member of various Swiss subsidiaries of foreign companies and other nonlisted Swiss companies. He is Member of the Board of Editors of the Swiss Review of Business Law and former Chairman of the Geneva Association of Business Law. Mr. von Planta is Chairman of the regulatory board of the SIX Swiss Exchange AG. Mr. von Planta holds Lizentiat des Rechts (lic. iur., LLB) and Doctorote in Philosophy (Ph.D.) degrees from Universitaet Basel, Switzerland, and an Master of Laws (LL.M.) from Columbia University School of Law, New York, United States.

Wendelin Wiedeking

Dr. Wendelin Wiedeking has been Member of the Board of Directors at Novartis AG since 2003. He qualifies as an independent Non-Executive Director. He is Member of the Audit and Compliance Committee and the Risk Committee of the Company. Dr. Wiedeking was Chairman of the Executive Board of Porsche Automobil Holding SE and of Dr. Ing. h.c. F. Porsche AG, both in Germany until July 2009. Since then he has been an entrepreneur. His professional career began in 1983 in Germany as Director’s Assistant in the Production and Materials Management area of Dr. Ing. h.c. F. Porsche AG in Stuttgart-Zuffenhausen. In 1988, he moved to Glyco Metall-Werke KG in Wiesbaden as Division Manager, where he advanced by 1990 to the position of Chief Executive Officer and Chairman of the Board of Management of Glyco AG. In 1991, he returned to Dr. Ing. h.c. F. Porsche AG as Production Director. A year later, the Supervisory Board appointed him Spokesman of the Executive Board (CEO), and Chairman in 1993. Dr. Wiedeking graduated in mechanical engineering in 1978 and worked as a scientific assistant in the Machine Tool Laboratory of the Rhine-Westphalian College of Advanced Technology in Germany.

Rolf Zinkernagel

Dr. Rolf M. Zinkernagel, M.D., serves as Member of the Board of Directors at Novartis AG since May 1999. He is Member of the Corporate Governance and Nomination Committee of the Company. Dr. Zinkernagel was Vice President of the International Union of Immunological Societies until 2010. He is Member of the scientific advisory boards of Bio-Alliance AG, Germany; Aravis General Partner Ltd., Cayman Islands and Switzerland; Telormedix, Switzerland; X-Biotech, Canada; Novimmune, Switzerland; Cancevir, Switzerland; Nuvo Research Inc., Canada; ImVision, Germany; MannKind, United States; and Biomedical Sciences International Advisory Council, Singapore. Dr. Zinkernagel is also a science consultant to Chilka Ltd., Cayman Islands; Ganymed, Germany; and Zhen-Ao Group, China. He is Member of the scientific advisory panel of Swiss Re, Switzerland. Dr. Zinkernagel graduated from Universitaet Basel, Switzerland, with a Doctor of Medicine (M.D.) in 1970. From 1992 to 2008, he was a professor and director of the Institute of Experimental Immunology at the University of Zurich and after his retirement in 2008, continues to be active at the University of Zurich. Dr. Zinkernagel has received awards and prizes for his work and contribution to science, notably the Nobel Prize in medicine, which he was awarded in 1996.

Verena Briner

Dr., Verena A. Briner, M.D., serves as Non-Executive Independent Member of the Board of Novartis AG since 2013. Dr. Briner is professor of internal medicine at the University of Basel, Switzerland, and chief medical officer and head of the department of medicine at the Lucerne Cantonal Hospital in Switzerland. She is a member of several medical and ethical institutions and commissions, including the board of the Foundation for the Development of Internal Medicine in Europe, the senate of the Swiss Academy of Medical Sciences, and the supervisory group for personalized medicine of the Centre for Technology Assessment TA-SWISS. She also is a member and former president of the Swiss Society of Internal Medicine. Dr. Briner graduated from the University of Basel with an M.D. in 1978, and has a specialized degree in internal medicine and nephrology from the Swiss Medical Association. She has received several prestigious scholarships and scientific grants, including the President’s Grant of the Society of General Internal Medicine in 2011, and is an honorary fellow of the American College of Physicians, the European Federation of Internal Medicine, the Polish Association of Internal Medicine, and the Swiss Society of General Internal Medicine. She was chief medical officer and department head at Swiss hospital; former president of Swiss medical society; member of various medical and ethical institutions and commissions.

Charles Sawyers

Dr. Charles L. Sawyers, M.D., has been Non-Executive Independent Member of the Board of Novartis AG since 2013. In the United States, Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center; professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences; and an investigator at the Howard Hughes Medical Institute. He serves on U.S. President Barack Obama’s National Cancer Advisory Board, and is president-elect of the American Association of Cancer Research, and former president of the American Society for Clinical Investigation. He also is a member of the U.S. National Academy of Sciences and Institute of Medicine. Dr. Sawyers received his M.D. from the Johns Hopkins School of Medicine in the United States, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles for nearly 18 years before joining Memorial Sloan-Kettering in 2006. He is cancer researcher; and co developed the Novartis cancer drug Gleevec/Glivec, and has received numerous honors and awards, including the Lasker- DeBakey Clinical Medical Research Award in 2009. He was program chair at cancer treatment and research institution; member of U.S. cancer advisory board; president-elect of organization; former president of medical honor society.

William Winters

Mr. William (Bill) T. Winters has been Non-Executive Independent Member of the Board of Novartis AG since 2013. Mr. Winters is chairman and CEO of Renshaw Bay, an alternative asset management and advisory company based in London. He is a former member of the UK Independent Commission on Banking, and served as co-CEO of JPMorgan’s investment banking business from 2003 to 2010. Mr. Winters received his bachelor’s degree from Colgate University and his Masters of Business Administration from the Wharton School at the University of Pennsylvania. He joined JPMorgan in 1983 and held management roles across several market areas and in corporate finance during his time there. Mr. Winters serves on the boards of Colgate University and the International Rescue Committee, both in the United States, and of the Young Vic Theatre and The Print Room, both in London. His leadership and Global experience include chairman and CEO of alternative asset management and advisory company; former co-CEO of investment banking at global financial services firm.

Samir Shah

Basic Compensation

Name Fiscal Year Total

Joerg Reinhardt

1,900,810

Joseph Jimenez

13,226,300

Ulrich Lehner

1,328,210

Harry Kirsch

2,344,290

Peter Kornicker

--

Felix Ehrat

4,321,510

Juergen Brokatzky-Geiger

3,524,740

Michele Galen

--

Paul van Arkel

--

Erwin Vanhaecke

--

Brian McNamara

3,043,130

Kevin Buehler

7,246,860

David Epstein

8,692,780

Mark Fishman

7,540,280

Jeffrey George

4,306,280

George Gunn

3,952,280

Andrin Oswald

3,418,120

Charlotte Pamer-Wieser

--

Dimitri Azar

450,020

William Brody

525,034

Srikant Datar

720,020

Ann Fudge

500,008

Pierre Landolt

431,407

Enrico Vanni

751,032

Andreas von Planta

589,079

Wendelin Wiedeking

476,933

Rolf Zinkernagel

684,418

Verena Briner

368,825

Charles Sawyers

350,043

William Winters

350,043

Samir Shah

--
As Of 30 Dec 2013
Search Stocks